Vaccine Distribution: Opportunities and Pitfalls
Four Duke scholars examine logistics, vaccinating children and ensuring poor nations aren't left out
Friday, December 04, 2020
Dear Duke Health and Duke University colleagues and staff: The FDA is planning to review the interim safety and efficacy data for the Pfizer/BioNTech COVID-19 vaccine on December 10th and the Moderna vaccine on December 17th as part of the process to consider COVID-19 vaccines for an emergency use authorization.
Quotes Dr. Ibukun Akinboyo, a pediatrician and infectious disease expert at Duke
Features comments by Thomas Denny, chief operating officer of Duke’s Human Vaccine Institute
Featuring the work and comments of assistant professor of biomedical sciences Amanda Randles and her team at Duke
Quotes Samuel Buell, a Duke University law professor and former federal prosecutor
Interview with Dr. Mark McClellan, director of the Duke-Margolis Center for Health Policy
Interview with Dr. Sarah Armstrong, a professor of pediatrics at Duke
Features comments by Dr. Joseph Rogers, chief medical officer for Duke Health
Commentary co-authored by William Darity Jr.
Quotes Dr. Thomas Holland, infectious disease doctor at Duke
Quotes Thomas Denny, chief operating officer of the Duke Human Vaccine Institute
Op-ed by political scientist Alexander Kirshner
Quotes James Cox, a professor of securities law at Duke, who explained that the absence of charges against a person or company can reflect a number of calculations.
Quotes Fuqua School adjunct professor Dorie Clark
Host Frank Stasio remembers the Duke historian
Mentions Duke’s involvement in project
Quotes Po-Chun Hsu, assistant professor of mechanical engineering and materials science
Cites an analyses from the Global Health Innovation Center